Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer

Cancer J. 2013 May-Jun;19(3):222-30. doi: 10.1097/PPO.0b013e318293238d.

Abstract

Over the last few decades, the integration of chemotherapy and radiation has played a crucial role in the management of locally advanced non-small cell lung cancer (NSCLC). Locally advanced NSCLC is a very heterogeneous disease. Because of this heterogeneity, advanced NSCLC can be managed in various ways depending on the bulk of disease, the comorbidities of the patient, and the expertise and resources of the treating physicians and facilities. This review describes the evolution of current treatment strategies and predicted future changes for the management of locally advanced NSCLC.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Chemoradiotherapy, Adjuvant
  • Clinical Trials as Topic
  • Dose Fractionation, Radiation
  • Humans
  • Lung Neoplasms / mortality
  • Lung Neoplasms / therapy*
  • Molecular Targeted Therapy
  • Postoperative Period
  • Preoperative Period
  • Treatment Outcome

Substances

  • Antineoplastic Agents